Eli Lilly and Company has announced the availability of Zepbound (tirzepatide) 2.5 mg and 5 mg single-dose vials for self-pay patients with an on-label prescription. This expansion significantly increases the supply of Zepbound in response to high demand for the obesity treatment.   The single-dose vials offer substantial cost savings compared to other incretin (GLP-1) medicines for obesity, priced at a 50% or greater discount to the list price. This new option provides broader access to Zepbo...